Clinical trial agreement negotiation, explained.

What a clinical trial agreement is: the contract that lets one hospital start one trial

One site agreement, from the sponsor's template to a site that may enroll

1. The sponsor sends the template and budgetNorthwind sends its CTA template and budget to Marlowe University Hospital. The protocol (the study's plan) and the consent form (what each participant reads and signs) move on their own tracks.
2. The site marks it upMarlowe's research contracts office, finance office and technology transfer office (which handles inventions) each edit the same Word file.
3. The sponsor answers every changeEach edit is read against the playbook and the last signed agreement: accepted, countered or sent to a lawyer. This is where the 19 changes and the two words on page 8 are handled.
4. Rounds repeat until both sides agreeEach round goes back to a queue at the other organization. Marlowe is on round 2.
5. Both sign, and the site can be activatedInstitution first, sponsor second. Ethics approval, training and drug supply finish on their own tracks. When all are done the site is activated, meaning cleared to enroll.

Step 3 is the subject of this guide. The people, companies and figures in this example are fictional.

Four surprises about CTAs: the waiting, a template that saves weeks, risky insurance wording and a missing count

Redline, playbook, fallback, walk-away: the words this work runs on

Fourteen terms are defined in the one-page summary.

The clause families in a CTA, and which ones answer to a document outside the contract

In shortA CTA is about a dozen families of clauses, each with its own owner. The useful question for each family is what else it has to agree with. A subject-injury clause has to match the consent form the ethics committee approved, a fee has to be a fair market price for the work, and a national model agreement may leave no room at all.

Read clause by clause, a CTA looks like one long legal document. Read family by family, it looks like a set of separate questions with separate owners. Scope and protocol belong to clinical operations, the team running the study. Payment terms belong to the budget owner. Publication belongs to contracts until a site asks for something new. Indemnity and liability, which decide who pays when someone sues, belong to a lawyer.

ICH E6(R3), the international guideline on good clinical practice, sets the frame. The sponsor should document its agreements with the investigator (the doctor leading the trial at the site) and institution "prior to initiating the activities", should document "the financial aspects of the trial" in an agreement, and should get the site's agreement to follow the protocol, keep records and permit monitoring, audit and inspection.6 The signed agreement is also listed among the trial's essential records, so an inspector can ask to see it.6

The twelve clause families, what sites usually ask for in each, and who answers

A 2012 survey of a clinical trials journal's subscribers, with 534 responses, named budget and payment, intellectual property, indemnification and liability, publication, insurance, and applicable law as the hardest topics to negotiate. It gives no ranking.12

The rules behind a site contract, and what changed for CTAs in 2025 and 2026

In shortNo US rule tells you what a CTA must say. Good clinical practice says what must be documented, and separate rules govern what the participant is told, what a payment may be worth and who pays Medicare back. The biggest recent changes are outside the US: a new UK suite of model agreements on April 28, 2026, and standard clauses in German law for contracts concluded after December 17, 2025.

How long clinical trial contract negotiation takes: 39 days to agree, 91 to fully sign

In shortThe best-known measurement comes from 29 US academic institutions: a median of 39 days to final negotiation and 91 to full execution, meaning every signature is on the page, with one site's median at 34 days and another's at 197. Standard agreements save weeks wherever they have been measured. Most of the data is old or self-reported, so treat it as a frame for your own numbers.

Those 29 institutions did not behave alike. Site medians ran from 3 to 116 days for negotiation and from 34 to 197 days for execution.1 A plan built on a single average hides a nearly sixfold spread between the fastest and slowest institutions on execution.

The same study gave the often-quoted comparison: a mean of 55 days to negotiate contract terms, which a master agreement (terms signed once and reused across studies) could bring down to 22, a cut of 33 days.1,3 Time to full execution did not fall significantly with a master agreement.1

A larger, later dataset measured a different thing. An analysis of 16,240 trials negotiated between 2010 and 2015 found Phase III budgets closing in a median of 28 days and Phase I in 46, with more than 23% of contract negotiations running beyond 60 days.27 In a 2012 survey, most respondents said negotiations usually take more than six weeks.12 A 2025 webinar slide says "90+ days to negotiate" as an industry average without giving its data.2 We lead with the measured 91.

Six network studies on one standard agreement: medians from 41 to 151 days

A shared template removes the argument over wording. It leaves queues, budgets and institutional sign-off in place.

What the Accelerated Clinical Trial Agreement and other standard templates save, in the studies that measured them

How a negotiation playbook works: preferred, two fallbacks, a walk-away and an authority line

In shortA playbook gives each clause family a ladder of answers: the preferred wording, two approved fallbacks, and a walk-away. A second decision, the authority line, says how far down that ladder a contracts manager may go without asking. Those two together decide how much reaches a lawyer.

The template already holds the preferred wording, so the value of a playbook lies in everything below it. Take the confidentiality family in the example. Northwind prefers seven years after the study ends. It will accept five years as a first fallback. It will accept an exception for public-records laws, with notice to the sponsor, as a second. Anything under five years, or no protection for the protocol at all, is the walk-away.

The authority line: how far down the ladder a contracts manager may go alone

The authority line is one setting: nothing, up to Fallback 1, or up to Fallback 2. Move it and the same redline splits differently. In the Marlowe redline, 13 of the 19 changes sit on an approved fallback. With authority at Fallback 2, all 13 can be accepted by the contracts manager. Drop the line to Fallback 1 and the changes that sit on Fallback 2 wait for a confirmation.

A change sitting past an approved position gets a counter at the nearest fallback. A change past the walk-away, or with no position at all, goes to its owner.

Write the line down. A year from now, someone may ask what the team was allowed to settle on the day a clause was accepted, and only a recorded setting answers that.

Precedent: what this institution already signed

The strongest reply to a site is its own signature. Marlowe signed an agreement with Northwind for another study, CRV-118, on March 14, 2024: a 45-day publication review with a 60-day patent delay, and an indemnity that keeps the protocol exclusion except for deviations made to protect a participant. When Marlowe now asks for 30 days and no patent delay, the counter is its own earlier wording. Two guards keep precedent honest: only fully signed agreements count, and old ones go stale as templates and laws change.

The rounds, in days: Marlowe on day 19 and Copperline on day 52

The rounds multiply the waiting. Each extra round adds the site's turnaround and the sponsor's. A sponsor cannot shorten the site's queue, but it can avoid creating another round by answering everything the first time. Sending four pre-approved items to legal with the two that need a lawyer adds the legal queue to all six.

Who pays when a trial injures someone: the subject injury clause, the consent form and Medicare

In shortThe subject-injury clause says who pays for treating a participant harmed by the study. The same promise appears in the consent form, written by other people and approved by an ethics committee (in the US, an institutional review board, or IRB), so the two have to match. In the US, wording that puts the participant's insurer first can create a Medicare problem, and Marlowe's ethics committee will not approve it in the example.

A subject is a trial participant, and the clause's old name sticks. The federal rule leaves the decision to pay with the sponsor and requires honesty about the answer: above minimal risk, the consent process must include "an explanation as to whether any compensation and an explanation as to whether any medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained".11 It also bars any language through which a participant waives or appears to waive legal rights.15

Because the promise to pay lives in the contract and the promise to the participant lives in the consent form, a mismatch is a real error. The consent form may say that a person will not be asked to use their own insurance first while the CTA says the sponsor pays only what insurance does not. A reviewer has to read both documents, and at most sponsors they sit with different teams.

Worked example: the insurance-first sentence Marlowe struck out

Rachel Kim's comment says that Marlowe's ethics committee will not approve consent language that leaves participants billing their own insurer first. Marlowe's approved form already says so. The sponsor's Fallback 1 says the same, so the fix is ready: remove the condition. Marlowe also asks that injury from the two study-only punch biopsies be covered, and the consent form covers "procedures done for the study". That is Fallback 2.

Why Medicare beneficiaries change the wording of a subject injury clause

Medicare pays second when another plan is responsible for the cost.5 CMS's answer on sponsors is short: "Payments made by sponsors of clinical trials for complications or injuries arising out of a clinical trial must be reported".18 One university's written position records that CMS, in an informal 2004 position, treats a sponsor's agreement to pay "if insurance denies" as triggering the secondary payer rules, leaving the sponsor responsible instead of Medicare.5

The Accelerated Clinical Trial Agreement carries its own passage on this reporting duty, and its injury clause leaves out any insurance-first condition.28

Subject injury by country: a negotiated promise in the US, a required system in the EU, fixed text in the UK

Clinical trial agreement indemnification: what "solely" and "gross" do to who pays

In shortIndemnity decides who pays when someone outside the contract sues. The sponsor normally covers claims from its drug and from protocol procedures, and excludes the site's own negligence. Small words decide how far that goes, so this family usually belongs with a lawyer. A deviation made to protect a participant is the usual compromise, and it appears in a published standard agreement.

An indemnity is a private promise to carry someone else's loss. In a CTA the claimant is usually a participant or their family. The sponsor says, in effect: if you are sued because of our drug or because you followed our protocol, we will defend you and pay. ICH E6(R3) marks the usual boundary: where the law calls for it, cover "against claims arising from the trial except for claims that arise from malpractice and/or negligence".6 Indemnity moves money only. Each party keeps its regulatory responsibility.6

The two indemnity edits in the Marlowe redline

Public institutions may be unable to give what the template asks

A site's edit sometimes reflects law, and a good reviewer can tell that from preference. Guidance from Ohio's Attorney General and one university's contracts office covers agreements with the state's universities. It says a provision requiring indemnification by the State is likely unconstitutional, because a state obligation needs a stated maximum amount. It also says the duty to answer public records requests cannot be limited by agreement.30,31

Rachel Kim's comments on Ohio law and Ohio public records in the example reflect that kind of constraint. Other states have their own rules, so a playbook needs a line for public institutions.

Liability caps and insurance: the requests that follow

Sites also ask for a limit on their own liability. In Germany the new standard clauses handle this directly. Liability for slight negligence is limited to typical, foreseeable damage where a material obligation was breached, and to the contract value for other breaches. Injury to life, limb or health sits outside those limits.8 One law firm notes that sponsors may want to check this with their insurers.24

Insurance is a separate clause. Sites ask for higher limits, proof of cover, or to be named on the policy. The ACTA asks the institution to carry at least $1,000,000 per occurrence and $3,000,000 in the annual aggregate, with allowances for public entities.28 A clause that names the institution as an additional insured, as Marlowe's does, changes the sponsor's policy itself, so the example's playbook answers with a certificate of insurance. The trial's insurance statement is listed among its essential records.6

Publication review days, patent delays and confidentiality terms: how published standards compare

In shortAcademic sites defend their right to publish and to own what they make independently. Sponsors defend a chance to protect patents and confidential data. Both sides now have published standards to point to, which makes these families good candidates for written fallbacks.

A sponsor's reasons for a review period are specific: to remove its confidential information and to file a patent before an idea becomes public. Neither published standard makes a site adopt a sponsor's edits. Under the ACTA, the site considers comments in good faith with "no obligation" to adopt them, and deletes confidential information only where that does not stop a complete and accurate presentation of the results.28 Under the German clause, the site weighs suggested changes only where they do not compromise scientific accuracy and neutrality.8

The timing of first publication is the other argument. Multicenter trials want one paper first, so a single site's early results do not skew the picture. The ACTA lets a site publish alone if no multicenter publication is submitted within 18 months after the study ends at all sites.28 The German clause gives the sponsor first publication and frees the site after 12 months, extendable by six months for scientific reasons set out in the protocol.8 Marlowe's ask for 12 months sits on Northwind's Fallback 2.

Confidentiality terms after the study: ten years in Germany, five in the ACTA

Inventions: what the study produced, and what the site made on its own

Sponsors expect to own inventions that come from their drug or their protocol. Academic institutions expect to keep what their people make independently. The usual fallback draws the line in those words: the institution keeps inventions made independently of the study drug and protocol, and without the sponsor's confidential information.

Inventions made with study samples are harder. In the example, Marlowe keeps them and offers the sponsor an exclusive six-month option to negotiate a license, which Northwind's playbook allows at Fallback 2. Copperline, another site in the example, asked for joint ownership, and that request went to legal. Germany's standard clauses cover rights to results and leave some employee-invention payment details to the parties.8,24

Records: who pays for storage that outlasts the study

US rules require investigators to keep records for 2 years after a marketing application is approved, or 2 years after the investigation is discontinued and FDA is notified.16 The EU requires the trial master file to be kept at least 25 years after the trial ends.20 ICH E6(R3) adds that the site agrees to keep essential records for the required period "or until the sponsor informs" it they are no longer needed, "whichever is longest".6

The usual negotiation is about who pays for the long storage, which is why Marlowe's edit sends archiving beyond 15 years to the sponsor at the budget's rates.

Clinical trial budget negotiation: fair market value, Open Payments and the fee nobody should wave through

In shortA payment to a site is regulated money. US fraud-and-abuse guidance expects fair market value for legitimate, reasonable and necessary services, and research payments are published each year in Open Payments, a public federal database. Payment mechanics can be pre-approved. A fee outside the benchmark needs its owner, a documented reason, and a place on the record.

The Office of Inspector General's 2003 guidance is short on this point: these contracts "should be structured to fit in the personal services safe harbor whenever possible", payments "should be fair market value for legitimate, reasonable, and necessary services", and prudent manufacturers "clearly separate the awarding of research contracts from marketing".9 A safe harbor is a set of conditions that protects a payment arrangement under the federal anti-kickback law. The guidance adds that research contracts originating in sales or marketing are "particularly suspect".9

That leaves four tests in one sentence: the amount, and whether the service is legitimate, reasonable and necessary. A fair hourly rate for work the protocol never asked for still fails.

Worked through: one screen-failure fee at a community hospital

A screen failure is a person who is assessed for the trial and turns out not to qualify. The site did the work, so it is paid something. In the example, Fernhill Regional Health, a site on another study, asks for 100% of the $1,840 Visit 1 fee. The sponsor's benchmark for this visit runs from 50% to 75%.

At the expected 21 screen failures, moving from 50% to 75% costs 21 × $460 = $9,660. The money is small. A fee above the range is a different kind of decision, so it goes to the budget owner.

Which budget lines Medicare's routine-cost rule puts on the sponsor

US sites build a coverage analysis: for each procedure in the protocol's schedule, can it be billed as routine care, or must the study pay? Medicare's rule leaves out "items and services customarily provided by the research sponsors free-of-charge for any enrollee in the trial" and anything done solely for data.10 The analysis decides what enters the budget. Budget arguments cluster around ordinary procedures done more often than care would need.

UK model clinical trial agreement, French convention unique, German standard clauses: when a site cannot negotiate

In shortSeveral countries publish their own agreement, and each one limits what a fallback can do. Offer a clause from your playbook to a site in the UK's National Health Service (NHS) and the agreement stops being the unaltered model, so it may need a separate submission. Check the country rule before you read a single clause.

What the April 2026 UK suite means for a template sitting in a start-up folder

The UK rule is an inventory problem. Existing contracts with NHS and health and social care organizations do not have to be updated or replaced, but any new contract entered into from April 28, 2026 must use the April 2026 version.7 So the copy attached to the kit of a contract research organization (CRO, a company hired to run parts of a trial), or the one a site returned from its last study, may be last year's edition.

Feedback goes to a group covering the four UK nations that "reviews feedback every 6 months".7 A clause a sponsor cannot live with belongs in a letter to that group.

What Germany's ordinance changes for a playbook written before December 2025

The clauses may differ from a global template in ways a negotiator should see. Confidentiality runs ten years after the trial ends. The site gives the sponsor a manuscript at least 45 days before submission, and the sponsor has 35 days to respond, extendable by up to 90 days to protect patents. Slight-negligence liability is limited as described in the indemnity section. The sponsor may terminate on 14 days' written notice.8 Because the two parties may agree to deviate,23 a sponsor can still propose other wording, and should expect pushback.24

Where CTA redline review goes wrong: missed changes, drifting concessions and consent form mismatches

In shortThe expensive mistakes share a shape: someone answers a clause without reading the other document it depends on, or lets a change pass unanswered. No regulator publishes error rates for this work. The list below comes from the rules themselves and from what practitioners report.

When a bad contract becomes a business problem: the 2012 survey's numbers

The only broad numbers we found are from a 2012 survey of 534 subscribers to a clinical trials journal, so they describe people who answered and a time before E6(R3). In it, 9% said their company had suffered damages from improperly negotiated site agreements. Over 6% said a CTA had been crucial to settling a suit or claim. Fewer than half tracked turnaround times, and most used a simple tool such as a spreadsheet. Then 80% said a previous bad experience with a site's contract negotiations influenced whether they worked with that site again.12

What a slow site agreement costs a study: site activation delays, sites that never start, and the day-of-delay figure

In shortAbout one selected site in nine never activates, with budgets and contracts the main reason given. A day of delay is now put at about $40,000 in direct trial cost and $500,000 to $800,000 in lost sales, depending on which Tufts publication you read, well below the old $4 to $5 million. A single late site rarely delays a whole trial, so count only the days that held up a milestone.

A site that does activate has already cost money. A 2012 paper on rare and selective cancer trials says the administrative process "takes 2–12 months per site" at "an estimated cost of $50,000 each", and that "it is common that 20–30% of study centers never enroll a patient on a given study".36 The authors call it an estimate and it is dated, but the shape holds: starting a site is paid for before anyone knows what it will return.

A day of delay: about $500,000 to $800,000 in lost sales, well below the old $4 to $5 million

Tufts CSDD published two sales figures in 2024 from one dataset of 645 drugs. Its journal article and an article in Applied Clinical Trials put a day of delay at about $500,000 in lost sales,38,39 and its August white paper at about $800,000.37 All three give about $40,000 in direct cost per day for Phase II and III together; the chart above splits them. The white paper says the widely quoted $4 to $5 million per day dates from estimates made in 1993.37 Check which version a slide is using.

The costs that a day-rate leaves out

AI contract review for clinical trials: what software can settle, and what regulators say about it

In shortReading tracked changes, matching them to a template and drafting a reply from approved wording are good uses of software, because the answer is already written down. Anything past the walk-away stays with a person. FDA's draft AI guidance sets aside uses of this kind, and the published results come from the people selling or using the tools.

What the published CTA automation results show, and who published them

Evidence is thin and comes from interested parties. In the 2025 webinar, which a contract software vendor's chief executive co-presented, one large academic center set goals of a 25% and then 50% cut in CTA review time, showed a new average of 25 days to sign, and reported that 71% of staff saved 1 to 3 hours per agreement within four months.2

A vendor's 2026 case study reports first-draft markups at one research institute falling from 17.5 to 10 days.40 Both describe site-side contracting, and both report what the teams report. We found no independent test of any tool's accuracy on CTA redlines as of November 2026. Part C sets out how to test one yourself.

The status of each AI rule, and whether it touches a site contract

The limits: where a contracts team should stay cautious

• A missed change is the worst failure, because silence reads as agreement. Check any tool's recall, the share of real changes it finds, before anything else.
• Tracked changes can miss edits. An edit made with tracking off shows only in a comparison against the template.
• A citation can be wrong. A confident placement with an invented rule survives review, so someone must be able to open the rule.
• Contracts are confidential. Check where the text goes, whether it trains a model, and what your agreement with each institution allows.
• Sending stays with a person. A reply that has reached the site cannot be withdrawn.

How sponsors negotiate site contracts today: who touches a CTA, and where a round's hours go

In shortA clinical contracts manager or a contract research organization runs each agreement, pulling in legal, budget and medical owners by email, while a site office does the same on the other side. Most working hours in a round go to reading and placing changes. Most calendar days are spent waiting.

Contracts manager to start-up lead: who touches a site agreement

One redline round, step by step, with its hand-offs

Where a contracts manager's hours go in a 20-change round

In-house, outsourced, a standard template or software: five ways of negotiating CTAs

The Marlowe redline: 13 changes accepted with their rules, 4 counters confirmed, 2 indemnity edits to the lawyer

In shortThis is the example from the top of the page, inside the product. Six agents read the 22-page redline and place each of its 19 changes on the sponsor's playbook in 34 seconds. Priya Ranvelle, the contracts manager, confirms four counters. Omar Haddad, legal counsel, gets the two indemnity edits with the walk-away quoted. A person sends the reply.

1

The redline arrives, exactly as Marlowe sent it

At 8:12 am on October 7, Marlowe_VLT-302_CTA_round2_redline.docx reaches the contracts mailbox from Rachel Kim. Priya sees 19 rows, each with the page, the section, the struck and inserted text, and Rachel's comment beside an empty playbook ladder.

Above the rows sits her authority setting: accept automatically up to Fallback 2. The clock reads day 19 of the 45-day target.

2

Six agents read it, each step in view

The redline reader maps 19 changes and 12 comments to template v2026.1. The playbook checker places them: 13 on an approved fallback, 4 past one but answerable with one, 2 with no approved position. The precedent finder pulls the CRV-118 agreement Marlowe signed on March 14, 2024, with 5 matching clauses.

The protocol and consent checker reads §10.2 and §10.3 against consent form v3.0 and protocol §10.4. The budget checker finds that no Exhibit B fee changed. The reply drafter writes the answers.

3

Thirty-four seconds later: 13, 4 and 2

A strip of 19 cells colors the whole redline by outcome. Seventeen changes resolve at an approved position. Each accepted row quotes the playbook line and its rule: payment in 30 days and a 5% holdback is Fallback 1 of PAY-04, and the five-year term is Fallback 1 of CON-02, which Marlowe also signed in 2024.

A diamond marks the reply on each ladder, a dot marks the site's ask, and a ring marks the 2024 precedent. Every automatic acceptance has an Undo, and nothing has gone to the site.

4

Two injury edits accepted, with the consent form behind them

Dropping the insurance-first condition is Fallback 1 of INJ-01, and Marlowe signed the same in 2024. Covering injury from the two study-only punch biopsies is Fallback 2. Consent form v3.0, approved by the site's ethics committee (IRB) on September 2, 2026, already promises both.

Inventions made independently of the study drug stay with Marlowe at Fallback 1 of IP-01, and an option to license sample inventions sits at Fallback 2.

5

Only the two indemnity edits go to legal

§9.1 deletes the protocol carve-out, and no approved position does that. The recommendation for Omar Haddad is Fallback 1: keep it, except for deviations made to protect a participant, the wording Marlowe signed for CRV-118.

§9.2 adds "solely" and "gross", which would make the sponsor pay for Marlowe's ordinary negligence. The rule IND-02 is quoted, and the recommendation is mutual indemnity at Fallback 2.

6

Four counters, each drafted at an approved fallback

Publication returns to 45 days plus the 60-day patent delay, as signed in 2024. Monitoring goes to 10 business days' notice with remote review kept. Insurance accepts $10,000,000 per occurrence and offers a certificate in place of additional insured status.

The $7,500 wind-down fee applies only if the study ends within six months of the first participant's enrollment. Priya confirms each one.

7

The reply, built from her decisions, sent by a person

The response redline shows accepted changes clean and the sponsor's changes tracked, each with a margin note. The cover email to Rachel Kim, copied to Dr. Elena Tarrow and Sam Patel, says 13 changes are accepted, 4 clauses carry wording that matches CRV-118, and 2 items are under internal review with a reply by October 10.

The .docx response and the Exhibit B budget are attached. Nothing reaches the site until Priya presses send.

The solution's design target is 45 days from template to signature. The product's sample dashboard shows a 33-day median and 84% of site changes settled inside the playbook, also targets, to be measured on your own agreements.

The clause board, signature runway, exceptions queue, playbook and dashboard, screen by screen

In shortOne redline is the story. These screens show the rest: moving the authority line, each clause with its evidence, the runway across every site, the owners' queue, the versioned playbook, the rounds by country and the settings that decide what may be settled.

Select any screen to open it larger. The sponsor, sites, people and figures are fictional. Clause wording, playbook lines and country rules on these screens are the product's sample text. For real clauses, use your counsel's drafting and the regulators' own text.

Six agents read the redline; the contracts manager, legal, budget and medical owners decide

In shortEach agent has one job and limits it does not cross. None of them sends anything to a site or changes the playbook. A named person confirms each counter, each owner decides what falls outside the playbook, and every decision is recorded.

Redline reader to reply drafter: the six CTA agents and what each must never do

Who decides each CTA change: the four-eyes rule across five owners

Under the four-eyes rule, the person who makes a decision and the one who checks it stay apart: a change the agents accept can be undone before sending, a counter needs a person, and an exception needs its owner.

Agent steps and human decisions are kept apart on the activity record, with name, date and time. Executed agreements carry signer, meaning, date and time. These are controls that support your compliance with good clinical practice, and with 21 CFR Part 11 and EU Annex 11, the US and EU rules on electronic records, where they apply to your records. Validation and the regulatory judgment stay yours. Botminds is SOC 2 Type II audited, and manages information security to ISO 27001.

Priya, Omar, Dana, Lena and Sam: the people in the Marlowe screens

From a site redline to a response: what the solution reads and writes

Systems a CTA negotiation rollout connects to

For each, ask whether it offers an API, a file feed or only screens, and who owns it. The solution runs from one study to a full portfolio, across countries and templates, inside the roles and access rules you set.

What a slow CTA costs you in contracts hours, legal time and sites that start late

In shortStart from your own numbers. Published figures frame the question: how long agreements take, how many sites never start, and what a delayed trial day costs. What matters to your decision is your rounds, your hours per round and how many of your changes never needed a lawyer. No one publishes those, so only you can measure them.

Timing five redline rounds to find your own baseline

The site lost, the term given away, and other costs a contracts calculator misses

What faster redline rounds return when you count contracts hours and legal time against the tool's cost

In shortPut in your own numbers. Every default marked illustrative is an assumption to replace. The calculator values contracts and legal hours alone, and shows delay on a separate line because a late site rarely holds up a whole trial.

Hours, escalations and rounds: where CTA automation can save

A return calculator for CTA contracting: agreements a year, hours per round and your hourly cost

A sponsor signing 120 site agreements a year at three rounds clears all three lines, the last only just. A sponsor signing 20 agreements a year, mostly on UK or French national templates, has few clauses to negotiate and probably should not buy this. Say so before anyone builds a business case.

How ready your clinical contracting team is: volume, a written playbook, precedent, ownership and sign-off

In shortPick the answer closest to your team today. Eight questions score 0 to 2, and the last is for reflection. The meter adds up your score as you go, and each question says why it matters and what a strong answer sounds like.

A low score means writing the fallback ladder before anything else

What to ask contract negotiation software about missed changes, citations, consent forms and sending

In shortAsk every vendor the same questions, us included. The answers show how much it reads, how you check each answer, who decides what, where your contracts go, and how you would measure it on your own closed redlines.

We found no published independent test of any vendor's accuracy on CTA redlines as of November 2026. A seeded-change replay on your own closed redlines is the fairest comparison, and the same test measures your current process.

Replay your closed redlines with seeded changes, then decide on four numbers

In shortWrite down your ladder, replay work you have already finished with changes you planted, and run one study in parallel with nothing automatic. None of these steps commits you to a vendor, and the written playbook is useful either way.

1. Time five rounds and count ten redlines, noting what reached legal and how many of those had a written answer.
2. Write the ladder for your most edited families, starting with the walk-away, and have your counsel own it.
3. Gather 20 to 30 closed rounds across institution types, countries, early and late rounds, including two that went badly. Fix the set, and copy some to plant changes.
4. Run one study in parallel with nothing automatic: your team still decides and sends every response.
5. Decide with four numbers: recall on changes, placement agreement, citation validity and escalation recall, then raise the line one rung if they earn it.

Recall, placement, citations and escalation: how to score a CTA pilot

Clinical trial agreement questions answered: timing, indemnification, subject injury, fair market value and AI review

In shortThe questions contract teams and buyers search for most, each answered on its own.